Replies to post #6422 on The Rising Influence of Rising Affluence

[DewDiligence]

ABT deferred discussion of Humira to ABBV’s CC on Jan 30. IMO, the 25% YoY growth can be attributed to: i) new approved indications; ii) price increases in the US; and ii) strong growth in emerging markets. We’ll know more about this next week.